Free Daily Headlines :

  • COVID-19
  • Vaccine Info
  • Money
  • Politics
  • Education
  • Health
  • Justice
  • More
    • Environment
    • Economic Development
    • Gaming
    • Investigations
    • Social Services
    • TRANSPORTATION
  • Opinion
    • CT Viewpoints
    • CT Artpoints
DONATE
Reflecting Connecticut’s Reality.
    COVID-19
    Vaccine Info
    Money
    Politics
    Education
    Health
    Justice
    More
    Environment
    Economic Development
    Gaming
    Investigations
    Social Services
    TRANSPORTATION
    Opinion
    CT Viewpoints
    CT Artpoints

LET�S GET SOCIAL

Show your love for great stories and out standing journalism

CT lawmakers push back on pharmaceutical issue in TPP

  • Health
  • by Ana Radelat
  • July 31, 2015
  • View as "Clean Read" "Exit Clean Read"
U.S. Rep. Rosa DeLauro, D-3rd District, speaks against the Trans Pacific Partnership fast track bill at a rally held a year ago by organized labor.

Creative commons photo by AGFE.

U.S. Rep. Rosa DeLauro, D-3rd District, speaks against the Trans Pacific Partnership fast track bill at a rally held a year ago by organized labor.

Washington – As negotiators for a massive Pacific Rim trade pact meet in Maui for a final round of talks, Connecticut lawmakers are pressing for changes they say would improve availability and prevent unaffordably high prices for medicines needed overseas and in the United States.

Last week, Rep. Jim Himes, D-4th District — along with 10 other Democrats who voted to give President Obama “fast track” authority to negotiate the Trans-Pacific Partnership — warned the administration they would not vote for a final agreement if it failed to allow for “timely access to affordable medicines in developing countries.”

The lawmakers had broken from most members of their party in giving Obama the authority to negotiate a trade pact that could not be changed by Congress, only voted up or down. But they said their loyalties to the administration might only go so far.

“At the conclusion of negotiations we will consider whether our constituents and country are better off with, or without, an agreement,” the lawmakers wrote U.S. Trade Representative Michael Froman.

Rep. Rosa DeLauro, D-3rd District, who joined organized labor, environmental groups and most Democrats in opposing the proposed TPP, has also been severely critical of the pharmaceutical provisions under discussion in this last round of talks.

She said they “confirm the worst fears of health care advocates” by restricting access to cheaper, generic prescription drugs in the dozen Pacific Rim countries that would sign on to the TPP.

“It is the U.S. (trade) representatives who have sided over and over again with the big pharmaceutical companies, in the face of opposition from other TPP countries,” DeLauro said at a press conference earlier this month.

American pharmaceuticals say they are trying to protect investments that result in lifesaving drugs.

“These protections allow our member companies to continue to develop and supply cutting-edge medicines that improve the health and quality of life of people around the globe,” said PhARMA, the trade association for the nation’s pharmaceuticals.

Under U.S. law, the U.S. pharmaceutical industry has 12 years of “data exclusivity,” the period during which generic versions of a drug manufactured using data generated by the original maker cannot be approved for sale by the Food and Drug Administration.

Supporters of a shorter timeline argue that it can take companies that make “biosimilars,” copies of complex, and usually very expensive biological drugs, six or seven years to make a generic. Biological drugs are made from living organisms and used to treat a growing number of diseases that now include cancer, AIDS, rheumatoid arthritis and diabetes.

There are no biosimilar drugs on the market in the United States today, but several are available in Asia.

The 11 Pacific Rim nations that would join the United States in the TPP have periods of exclusivity that range from zero to 12 years. The exclusivity period in Japan and Canada is eight years. The exclusivity period in Australia, which is pushing back the hardest in the latest round of trade talks, is five years.

The AARP and others want that period of exclusivity to be seven years or less in the United States, as does the generic drug industry. President Obama says he does, too, even as his administration’s negotiators are pushing for the 12-year timetable.

So has Connecticut Gov. Dannel Malloy, putting him at odds with other Democrats like DeLauro and Himes who are trying to give other TPP countries more flexibility.

In 2011, Malloy and a group of elected officials that included five other governors, asked Obama to insist U.S. trading partners under the TPP adopt the 12-year U.S. standard, which is longer than in Canada and Mexico and most countries in Europe and Asia. They said the biopharmaceutical sector supports more than three million U.S. jobs.

AARP, Doctors Without Borders (Medicines Sans Frontieres) and other patient advocates are pressing TPP negotiators to allow other countries to develop their own timelines.

AARP lobbyist Nancy LeaMond says the “anticompetitive provision” under discussion in Hawaii includes extending brand drug patent protections through “evergreening,” or creating a new drug from a slightly modified older drug to extend intellectual property protections.

As biosimilars become available in the United States, LeMond said, it’s critical Congress not be tied into 12 years by a trade pact that prevents it from considering policy changes that would allow these less expensive follow-on biologics to come to market sooner.

LeaMond also said she is concerned about the TPP’s adoption of “patent linkage,” which would block a nation’s regulatory agency from granting marketing approval to a generic drug if it is alleged there is a patent in another country for a similar drug.

“These provisions are all designed to ensure monopoly control by brand-name drug companies,” LeaMond said.

Pharma lobbies on the TPP

Himes said there should be a “balance” between the interests of pharmaceuticals and the protection of access to live-saving drugs for those in developing countries who need them.

The letter he and his Democratic colleagues sent the USTR last week urged negotiators to change course and adjust the pharmaceutical provisions by making them consistent with a trade pact negotiated with Peru, Panama and Colombia that gave those companies flexibilities with their timelines.

“Big pharmaceuticals need to recuperate their investment or they won’t incur the expense of research and development of creating new drugs,” Himes said. “But there’s also a flip side. It’s also critical that we have life-saving medicines available to people who can’t afford expensive drugs.”

The USTR did not respond to several requests for comment on the lawmaker’s concerns.

Himes said he’s hoping for a “good set of standards.”

But, according to a Sunlight Foundation study, the U.S. pharmaceutical industry has been lobbying for their interest in the Trans Pacific Partnership for years.

The report said that as early as 2009, years before the Trans-Pacific Partnership began to be widely debated, 28 organizations filed 59 lobbying reports mentioning the then far-off trade agreement. Almost half of those organizations were pharmaceutical companies or associations, the report said.

“It was an early clue as to which industry would take the most active role in trying to shape the trade agreement while it was still secret from the public,” Sunlight said.

The report listed Pfizer as the most active company lobbying on the TPP, at least measured by the number of lobbying reports filed between 2009 and 2013 that mentioned the proposed trade pact — more than 40.

“Our lobbying efforts are guided by two main principles — maintaining and improving incentives for innovation as well as protecting and expanding access to medicines,” said Pfizer spokeswoman Sharon Castillo.

Meanwhile, the Obama administration hopes the agreement, which would cover 40 percent of the global economy, will be completed in the next few days or weeks to give Congress enough time to act on it before the end of the year — and before the Trans Pacific Partnership gets mired in 2016 presidential election year politics.

Sign up for CT Mirror's free daily news summary.

Free to Read. Not Free to Produce.

The Connecticut Mirror is a nonprofit newsroom. 90% of our revenue comes from people like you. If you value our reporting please consider making a donation. You'll enjoy reading CT Mirror even more knowing you helped make it happen.

YES, I'LL DONATE TODAY

ABOUT THE AUTHOR

Ana Radelat Ana has written about politics and policy in Washington, D.C.. for Gannett, Thompson Reuters and UPI. She was a special correspondent for the Miami Herald, and a regular contributor to The New York TImes, Advertising Age and several other publications. She has also worked in broadcast journalism, for CNN and several local NPR stations. She is a graduate of the University of Maryland School of Journalism.

SEE WHAT READERS SAID

RELATED STORIES
CT budget leaders want to use massive savings to expand COVID-19 relief
by Keith M. Phaneuf

Gov. Ned Lamont’s administration expects to spend about $630 million less than legislators authorized.

The game is changing. Chris Murphy says he’s ready to play.
by Mark Pazniokas

The question for Sen. Chris Murphy no longer is where might he go next, but what can he do now.

More than 300 teachers vaccinated at Southbury clinic; State says older residents should come first
by Dave Altimari

Some teachers are getting vaccinated while the state is trying to get the COVID-19 vaccine out to older residents first.

Joe Biden takes office: ‘At this hour, my friends, democracy has prevailed.’
by Mark Pazniokas

America took a deep breath and watched Joe Biden uneventfully inaugurated outside a Capitol invaded two weeks ago by rioters.

Lamont sets the stage for a debate on marijuana taxation by mid-2022
by Keith M. Phaneuf

The governor's draft bill proposes taxing marijuana and erasing convictions for possession that occurred prior to Oct. 1, 2015.

Support Our Work

Show your love for great stories and outstanding journalism.

$
Select One
  • Monthly
  • Yearly
  • Once
Artpoint painter
CT ViewpointsCT Artpoints
Opinion Connecticut’s $100 million college shell game
by Stephen Adair

The plan to consolidate the 12 community colleges in Connecticut into one college with 12 campuses is called “Students First,” which is ironic because it does not fund students first.  It funds a new administration in a new, statewide bureaucracy. The Board of Regents (BOR) and the Connecticut State Colleges and Universities (CSCU) system office […]

Opinion Inconsistent television captioning is a barrier to equal access
by Jeffrey Bravin and Barbara Cassin

Our world long ago entered the age of the 24-hour news cycle, and a full understanding of the “who, what, when, where and why” of the news is critical for deaf, deafblind and hard of hearing citizens. Yet, Connecticut’s inconsistent quality of television captioning locks our community out of the complete sense of what is happening.

Opinion A just stimulus package is a start toward true racial inclusion
by Carlton L Highsmith

For centuries Blacks have been denied full participation in the American Dream. But for the sake of our collective progress, as we recover from the crippling economic effects of COVID-19, our country has a mandate to acknowledge its history of systematic institutionalized exclusionary practices and not repeat them.

Opinion Hamden taxpayers are left in the dark
by Lauren Garrett

“A budget is a moral document.” This phrase is often heard during budget season from both sides of the aisle advocating for their personal values. The municipal operating budget is the cost of running a town which includes paying for employees, schools, and other services. Asking residents to pay property taxes requires a public trust.

Artwork Grand guidance
by Anne:Gogh

In a world of systemic oppression aimed towards those of darker skintones – representation matters. We are more than our equity elusive environments, more than numbers in a prison and much more than victims of societal dispositions. This piece depicts a melanated young man draped in a cape ascending high above multiple forms of oppression. […]

Artwork Shea
by Anthony Valentine

Shea is a story about race and social inequalities that plague America. It is a narrative that prompts the question, “Do you know what it’s like to wake up in new skin?”

Artwork The Declaration of Human Rights
by Andres Chaparro

Through my artwork I strive to create an example of ideas that reflect my desire to raise social consciousness, and cultural awareness. Jazz music is the catalyst to all my work, and plays a major influence in each piece of work.”

Artwork ‘A thing of beauty. Destroy it forever’
by Richard DiCarlo | Derby

During times like these it’s often fun to revisit something familiar and approach things with a different slant. I have been taking some Pop culture and Art masterpieces and applying the vintage 1960’s and 70’s classic figures (Fisher Price, little people) to the make an amusing pieces. Here is my homage to Fisher -Price, Yellow […]

Twitter Feed
A Twitter List by CTMirror

Engage

  • Reflections Tickets & Sponsorships
  • Events
  • Donate
  • Newsletter Sign-Up
  • Submit to Viewpoints
  • Submit to ArtPoints
  • Economic Indicator Dashboard
  • Speaking Engagements
  • Commenting Guidelines
  • Legal Notices
  • Contact Us

About

  • About CT Mirror
  • Announcements
  • Board
  • Staff
  • Sponsors and Funders
  • Donors
  • Friends of CT Mirror
  • History
  • Financial
  • Policies
  • Strategic Plan

Opportunity

  • Advertising and Sponsorship
  • Speaking Engagements
  • Use of Photography
  • Work for Us

Go Deeper

  • Steady Habits Podcast
  • Economic Indicator Dashboard
  • Five Things

The Connecticut News Project, Inc. 1049 Asylum Avenue, Hartford, CT 06105. Phone: 860-218-6380

© Copyright 2021, The Connecticut News Project. All Rights Reserved. Website by Web Publisher PRO